Nishan de Silva

Nishan de Silva, M.D., M.B.A. has over 25 years of experience in healthcare, spanning management consulting, life sciences private equity investing, and biotechnology C-suite and Board of Director roles in public and private biopharmaceutical companies. He began his career at McKinsey & Company, then served as a Principal at Warburg Pincus, leading and managing $30–100M investments in biotech firms and serving on multiple Boards. Over the next 12 years, Dr. de Silva held C-suite roles at public and private venture-backed biotech companies. He was CFO and Head of Strategy at Ligand Pharmaceuticals, where market capitalization grew from ~$200M to ~$2B during his tenure; President & COO at Poseida Therapeutics, acquired by Roche for up to $1.5B; and CEO of Radionetics Oncology and AFYX Therapeutics (both private venture capital-backed companies). He currently serves on the Board of Cartesian Therapeutics.  His career reflects a strong track record in strategy, financing, and growth across the biotech sector.